Watertown’s Selecta will license technology to speed gene therapy development – The Boston Globe
Xconomy |
Watertown's Selecta will license technology to speed gene therapy development
The Boston Globe Under the agreement, eight-year-old Selecta — which went public in June — will license its proprietary synthetic vaccine particles technology to Philadephia-based Spark for use in experimental gene therapies targeting hemophilia A and up to four … Fresh Off ASH Data, Spark Teams With Selecta to Boost Gene Therapies Spark Therapeutics licenses nanoparticle technology for possible use in gene therapy Spark teams up with Selecta on gene therapies |
